688302 海创药业-U
已收盘 08-28 15:00:00
资讯
新帖
简况
海创药业（688302）披露2026年半年度报告，8月26日股价下跌1.4%
证券之星 · 08-26 22:22
海创药业（688302）披露2026年半年度报告，8月26日股价下跌1.4%
每周股票复盘：海创药业（688302）氘恩扎鲁胺启动BCR前列腺癌Ⅲ期临床
证券之星 · 07-19
每周股票复盘：海创药业（688302）氘恩扎鲁胺启动BCR前列腺癌Ⅲ期临床
海创药业：氘恩扎鲁胺软胶囊临床试验获批准
证券之星 · 07-15
海创药业：氘恩扎鲁胺软胶囊临床试验获批准
每周股票复盘：海创药业（688302）核心产品上市并进医保，公司调整研发策略
证券之星 · 06-28
每周股票复盘：海创药业（688302）核心产品上市并进医保，公司调整研发策略
海创药业（688302）披露关于2025年年度报告信息披露监管问询函的专项核查意见，6月26日股价下跌5.22%
证券之星 · 06-26
海创药业（688302）披露关于2025年年度报告信息披露监管问询函的专项核查意见，6月26日股价下跌5.22%
每周股票复盘：海创药业（688302）HP515临床试验达主要终点
证券之星 · 06-20
每周股票复盘：海创药业（688302）HP515临床试验达主要终点
海创药业（688302）披露HP515治疗MASH临床IIa期试验最终分析结果，6月16日股价上涨3.89%
证券之星 · 06-16
海创药业（688302）披露HP515治疗MASH临床IIa期试验最终分析结果，6月16日股价上涨3.89%
海创药业(688302.SH)：治疗代谢相关脂肪性肝炎(MASH)药物HP515临床IIa期试验取得最终分析结果
智通财经 · 06-15
海创药业(688302.SH)：治疗代谢相关脂肪性肝炎(MASH)药物HP515临床IIa期试验取得最终分析结果
海创药业：MASH药物HP515临床IIa期试验达主要终点
证券之星 · 06-15
海创药业：MASH药物HP515临床IIa期试验达主要终点
海创药业（688302）披露2025年年度股东会决议公告，5月18日股价下跌0.34%
证券之星 · 05-18
海创药业（688302）披露2025年年度股东会决议公告，5月18日股价下跌0.34%
每周股票复盘：海创药业（688302）首款1类新药上市贡献收入2046.99万元
证券之星 · 05-17
每周股票复盘：海创药业（688302）首款1类新药上市贡献收入2046.99万元
海创药业（688302）披露持续督导保荐总结报告书，5月13日股价下跌2.51%
证券之星 · 05-13
海创药业（688302）披露持续督导保荐总结报告书，5月13日股价下跌2.51%
每周股票复盘：海创药业（688302）首款新药上市贡献收入2019.25万元
证券之星 · 05-10
每周股票复盘：海创药业（688302）首款新药上市贡献收入2019.25万元
海创药业（688302）披露2025年年度股东会会议资料，5月8日股价上涨2.92%
证券之星 · 05-08
海创药业（688302）披露2025年年度股东会会议资料，5月8日股价上涨2.92%
4月30日海创药业涨7.95%，鹏华医药科技股票A基金重仓该股
证券之星 · 04-30
4月30日海创药业涨7.95%，鹏华医药科技股票A基金重仓该股
海创药业：治疗MASH药物HP515临床IIa期试验期中分析获积极结果
证券之星 · 04-27
海创药业：治疗MASH药物HP515临床IIa期试验期中分析获积极结果
4月27日海创药业跌12.16%，鹏华医药科技股票A基金重仓该股
证券之星 · 04-27
4月27日海创药业跌12.16%，鹏华医药科技股票A基金重仓该股
海创药业(688302)3月31日股东户数0.8万户，较上期减少3.02%
证券之星 · 04-25
海创药业(688302)3月31日股东户数0.8万户，较上期减少3.02%
图解海创药业年报：第四季度单季净利润同比增长16.11%
证券之星 · 04-25
图解海创药业年报：第四季度单季净利润同比增长16.11%
创新药概念午后再度活跃 海创药业涨超11%
每日经济新闻 · 03-31
创新药概念午后再度活跃 海创药业涨超11%
暂无数据
公司概况
公司名称：
海创药业股份有限公司
所属行业：
医药制造业
上市日期：
2022-04-12
主营业务：
海创药业股份有限公司的主营业务是药品的研发、生产、销售以及技术咨询、技术转让。公司的主要产品是海纳安、HP518、HP537、HP515、GLP小分子、HP570、HC-X049。
发行价格：
42.92
{"stockData":{"symbol":"688302","market":"SH","secType":"STK","nameCN":"海创药业-U","latestPrice":33.82,"timestamp":1787900400000,"preClose":34.24,"halted":0,"volume":1184167,"delay":0,"changeRate":-0.0123,"floatShares":99015600,"shares":99015600,"eps":-1.3293,"marketStatus":"已收盘","change":-0.42,"latestTime":"08-28 15:00:00","open":34.5,"high":34.59,"low":33.69,"amount":40494300,"amplitude":0.0263,"askPrice":33.9,"askSize":22,"bidPrice":33.82,"bidSize":40,"shortable":0,"etf":0,"ttmEps":-1.3293,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":5,"adr":0,"adjPreClose":34.24,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787880600000,1787887800000],[1787893200000,1787900400000]],"highLimit":37.66,"lowLimit":30.82,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":99015598,"isCdr":false,"pbRate":3.32,"roa":"--","roe":"--","epsLYR":-1.39,"committee":0.226481,"marketValue":3349000000,"turnoverRate":0.012,"status":1,"afterMarket":{"amount":0,"volume":0,"close":33.82,"buyVolume":0,"sellVolume":0,"time":1787902437746,"indexStatus":"已收盘 08-28 15:30:00","preClose":34.24},"floatMarketCap":3349000000},"requestUrl":"/m/hq/s/688302/tweets","defaultTab":"tweets","newsList":[{"id":"2662710641","title":"海创药业（688302）披露2026年半年度报告，8月26日股价下跌1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662710641","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662710641?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:22","pubTimestamp":1787754153,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘，海创药业报收于34.55元，较前一交易日下跌1.4%，最新总市值为34.21亿元。该股当日开盘35.05元，最高35.8元，最低34.0元，成交额达5256.4万元，换手率为1.53%。近日，海创药业股份有限公司披露《2026年半年度报告》。本报告期实现营业收入54,970,550.02元，同比增长317.48%；归属于上市公司股东的净利润为-56,218,129.78元，上年同期为-61,853,200.96元。研发投入占营业收入的比例为104.92%，较上年同期减少327.73个百分点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600052909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652123011","title":"每周股票复盘：海创药业（688302）氘恩扎鲁胺启动BCR前列腺癌Ⅲ期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2652123011","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652123011?lang=zh_cn&edition=full","pubTime":"2026-07-19 02:43","pubTimestamp":1784400187,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，海创药业报收于37.0元，较上周的38.6元下跌4.15%。本周关注点公司公告汇总：氘恩扎鲁胺软胶囊获准开展高风险生化复发前列腺癌Ⅲ期临床试验。该适应症此前国内无获批药物，氘恩扎鲁胺的获批填补了临床空白。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651546853","title":"海创药业：氘恩扎鲁胺软胶囊临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651546853","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651546853?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:00","pubTimestamp":1784116848,"startTime":"0","endTime":"0","summary":"海创药业(688302.SH)公告称，公司收到中国国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意氘恩扎鲁胺软胶囊开展前列腺癌Ⅲ期临床实验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500040970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646316680","title":"每周股票复盘：海创药业（688302）核心产品上市并进医保，公司调整研发策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2646316680","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646316680?lang=zh_cn&edition=full","pubTime":"2026-06-28 04:14","pubTimestamp":1782591252,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，海创药业报收于33.06元，较上周的35.55元下跌7.0%。公司公告汇总中信证券就海创药业2025年年度报告信息披露监管问询函进行核查并发表意见。公司核心产品氘恩扎鲁胺软胶囊于2025年5月在国内获批上市，用于治疗转移性去势抵抗性前列腺癌，已纳入国家医保目录。海创药业就上交所对公司2025年年度报告的信息披露监管问询函作出回复，内容涉及研发进展、主营收入、建设项目及其他事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646661503","title":"海创药业（688302）披露关于2025年年度报告信息披露监管问询函的专项核查意见，6月26日股价下跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646661503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646661503?lang=zh_cn&edition=full","pubTime":"2026-06-26 23:06","pubTimestamp":1782486380,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，海创药业报收于33.06元，较前一交易日下跌5.22%，最新总市值为32.73亿元。该股当日开盘34.58元，最高34.88元，最低32.66元，成交额达5046.17万元，换手率为1.53%。公告显示，中信证券就海创药业2025年年度报告信息披露监管问询函进行核查并发表意见。2025年公司实现营业收入2,047万元，研发费用11,270.77万元。成都生产基地于2026年1月底通过GMP检查，实现制剂自产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600046246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644652850","title":"每周股票复盘：海创药业（688302）HP515临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2644652850","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644652850?lang=zh_cn&edition=full","pubTime":"2026-06-20 03:09","pubTimestamp":1781896191,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，海创药业报收于35.55元，较上周的34.27元上涨3.74%。本周，海创药业6月18日盘中最高价报35.8元。6月15日盘中最低价报33.14元。海创药业当前最新总市值35.2亿元，在化学制药板块市值排名112/150，在两市A股市值排名4018/5206。药物总体耐受性良好，未发生严重不良事件。公司已完成I期临床试验，HP515已获中美监管部门批准开展MASH适应症临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000001883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759069","title":"海创药业（688302）披露HP515治疗MASH临床IIa期试验最终分析结果，6月16日股价上涨3.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759069","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643759069?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:01","pubTimestamp":1781607671,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，海创药业报收于34.73元，较前一交易日上涨3.89%，最新总市值为34.39亿元。近日，海创药业发布《自愿披露关于治疗代谢相关脂肪性肝炎药物HP515临床IIa期试验取得最终分析结果的公告》。公告显示，公司自主研发的HP515片在治疗代谢相关脂肪性肝炎的IIa期临床试验中达到主要终点和关键次要终点。公司已完成I期临床试验，HP515已获中美监管部门批准开展MASH适应症临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600036845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643515208","title":"海创药业(688302.SH)：治疗代谢相关脂肪性肝炎(MASH)药物HP515临床IIa期试验取得最终分析结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2643515208","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643515208?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:32","pubTimestamp":1781523142,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海创药业(688302.SH)发布公告，公司自主研发的拟用于治疗代谢相关脂肪性肝炎(MASH，曾用名非酒精性脂肪性肝炎(NASH))的1类创新药物HP515片的临床IIa期试验最终分析结果达到主要终点和关键次要终点。该试验结果表明HP515片能显著改善肝脂肪代谢，同时可以改善血脂异常，而且其总体安全性良好。该试验最终分析结果达到主要终点和关键次要终点，对公司近期经营业绩不会产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海创药业(688302.SH)：治疗代谢相关脂肪性肝炎(MASH)药物HP515临床IIa期试验取得最终分析结果","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643227069","title":"海创药业：MASH药物HP515临床IIa期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2643227069","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643227069?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:01","pubTimestamp":1781521261,"startTime":"0","endTime":"0","summary":"海创药业(688302.SH)公告称，公司自主研发的MASH药物HP515片临床IIa期试验最终分析结果达到主要终点和关键次要终点。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500027207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636222700","title":"海创药业（688302）披露2025年年度股东会决议公告，5月18日股价下跌0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636222700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636222700?lang=zh_cn&edition=full","pubTime":"2026-05-18 18:40","pubTimestamp":1779100835,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，海创药业报收于43.55元，较前一交易日下跌0.34%，最新总市值为43.12亿元。该股当日开盘43.99元，最高44.5元，最低43.03元，成交额达4100.11万元，换手率为0.95%。近日，海创药业股份有限公司披露《2025年年度股东会决议公告》。所有议案均获通过，无否决议案。会议表决程序合法有效，律师出具了见证意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800029851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636488062","title":"每周股票复盘：海创药业（688302）首款1类新药上市贡献收入2046.99万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636488062","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636488062?lang=zh_cn&edition=full","pubTime":"2026-05-17 04:45","pubTimestamp":1778964312,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，海创药业报收于43.7元，较上周的45.43元下跌3.81%。本周，海创药业5月12日盘中最高价报46.3元。海创药业当前最新总市值43.27亿元，在化学制药板块市值排名108/150，在两市A股市值排名3848/5203。中信证券在2025年度持续督导跟踪报告中指出，公司首个1类新药氘恩扎鲁胺软胶囊获批上市，实现营业收入2,046.99万元，净亏损收窄至-13,725.26万元，研发费用同比下降35.24%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635788900","title":"海创药业（688302）披露持续督导保荐总结报告书，5月13日股价下跌2.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635788900","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635788900?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:09","pubTimestamp":1778666994,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，海创药业报收于44.75元，较前一交易日下跌2.51%，最新总市值为44.31亿元。近日，海创药业披露《中信证券股份有限公司关于海创药业股份有限公司持续督导保荐总结报告书》。公告显示，中信证券作为保荐人对海创药业首次公开发行股票并在科创板上市履行持续督导职责，持续督导期至2025年12月31日届满。截至督导期末，部分募集资金尚未使用完毕，保荐人将继续履行监督义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300033886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634414828","title":"每周股票复盘：海创药业（688302）首款新药上市贡献收入2019.25万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634414828","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634414828?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:13","pubTimestamp":1778350390,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，海创药业报收于45.43元，较上周的44.0元上涨3.25%。本周，海创药业5月8日盘中最高价报47.07元。海创药业当前最新总市值44.98亿元，在化学制药板块市值排名108/150，在两市A股市值排名3798/5200。报告期内，公司首款新药氘恩扎鲁胺软胶囊获批上市，实现销售收入2019.25万元，并已纳入国家医保目录。2025年公司营业收入为2046.99万元，净亏损13725.26万元，经营活动现金流净额为-10887.83万元。由于累计未分配利润为负，2025年度不进行利润分配。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633392564","title":"海创药业（688302）披露2025年年度股东会会议资料，5月8日股价上涨2.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633392564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633392564?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:27","pubTimestamp":1778232432,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，海创药业报收于45.43元，较前一交易日上涨2.92%，最新总市值为44.98亿元。该股当日开盘44.13元，最高47.07元，最低43.51元，成交额达1.1亿元，换手率为2.43%。海创药业于近日披露《2025年年度股东会会议资料》。公告显示，公司2025年年度股东大会定于2026年5月15日召开，采用现场与网络投票相结合的方式。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800031176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631685732","title":"4月30日海创药业涨7.95%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2631685732","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631685732?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:26","pubTimestamp":1777537618,"startTime":"0","endTime":"0","summary":"证券之星消息，4月30日海创药业涨7.95%，收盘报44.0元，换手率2.37%，成交量2.35万手，成交额9947.52万元。该股为创新药、医药概念热股。重仓海创药业的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为16.53亿元，最新净值1.6892，较上一交易日上涨0.33%，近一年上涨24.55%。该公募基金现任基金经理为金笑非。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000053477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","159938","BK1574","BK0239","09939","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630608033","title":"海创药业：治疗MASH药物HP515临床IIa期试验期中分析获积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2630608033","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630608033?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:29","pubTimestamp":1777285782,"startTime":"0","endTime":"0","summary":"海创药业公告称，公司自主研发的治疗代谢相关脂肪性肝炎药物HP515临床IIa期试验取得期中分析积极结果。安全性方面，各剂量组总体耐受性良好，未报告严重不良事件、重度不良事件或与药物相关的退出，绝大多数不良事件为轻中度且呈一过性。截至公告日，国内无同类靶点产品获批上市。该结果对公司近期经营业绩无重大影响，投资者需注意研发及市场风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700034581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630336631","title":"4月27日海创药业跌12.16%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630336631","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630336631?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:29","pubTimestamp":1777278550,"startTime":"0","endTime":"0","summary":"证券之星消息，4月27日海创药业跌12.16%，收盘报41.03元，换手率3.15%，成交量3.12万手，成交额1.32亿元。重仓海创药业的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为16.53亿元，最新净值1.6872，较上一交易日下跌0.5%，近一年上涨24.07%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700029243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","09939","688302","BK1515","BK0239","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630870303","title":"海创药业(688302)3月31日股东户数0.8万户，较上期减少3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630870303","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630870303?lang=zh_cn&edition=full","pubTime":"2026-04-25 17:06","pubTimestamp":1777108009,"startTime":"0","endTime":"0","summary":"证券之星消息，近日海创药业披露，截至2026年3月31日公司股东户数为7984.0户，较12月31日减少249.0户，减幅为3.02%。在化学制药行业个股中，海创药业股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.52万户。从股价来看，2025年12月31日至2026年3月31日，海创药业区间跌幅为10.47%，在此期间股东户数减少249.0户，减幅为3.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500032218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630829710","title":"图解海创药业年报：第四季度单季净利润同比增长16.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630829710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630829710?lang=zh_cn&edition=full","pubTime":"2026-04-25 01:26","pubTimestamp":1777051575,"startTime":"0","endTime":"0","summary":"证券之星消息，海创药业2025年年报显示，当年度公司主营收入2046.99万元，同比上升5480.11%；归母净利润-1.37亿元，同比上升31.2%；扣非净利润-1.68亿元，同比上升22.82%；其中2025年第四季度，公司单季度主营收入-288.19万元，同比下降1220.93%；单季度归母净利润-3810.54万元，同比上升16.11%；单季度扣非净利润-4796.7万元，同比上升4.39%；负债率18.8%，投资收益518.41万元，财务费用-634.89万元，毛利率98.62%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500004149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623308309","title":"创新药概念午后再度活跃 海创药业涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623308309","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2623308309?lang=zh_cn&edition=full","pubTime":"2026-03-31 13:50","pubTimestamp":1774936200,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月31日，创新药概念午后再度活跃，海创药业涨超11%，此前津药药业、凯莱英涨停，双鹭药业、首药控股、亚太药业、威尔药业、万邦德、诚达药业跟涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603313690242481.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690242481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","06978","688302","159992","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787904937070,"stockEarnings":[{"period":"1week","weight":-0.1008},{"period":"1month","weight":0.031},{"period":"3month","weight":-0.1384},{"period":"6month","weight":-0.2252},{"period":"1year","weight":-0.4151},{"period":"ytd","weight":-0.3036}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0376},{"period":"3month","weight":-0.0275},{"period":"6month","weight":-0.0496},{"period":"1year","weight":0.0411},{"period":"ytd","weight":-0.0031}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"海创药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7146人(较上一季度减少10.50%)","perCapita":"13856股","listingDate":"2022-04-12","address":"四川省成都市双流区凤凰路558号","registeredCapital":"9901万元","survey":" 海创药业股份有限公司的主营业务是药品的研发、生产、销售以及技术咨询、技术转让。公司的主要产品是海纳安、HP518、HP537、HP515、GLP小分子、HP570、HC-X049。","listedPrice":42.92},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海创药业-U(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海创药业-U(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海创药业-U,688302,海创药业-U股票,海创药业-U股票老虎,海创药业-U股票老虎国际,海创药业-U行情,海创药业-U股票行情,海创药业-U股价,海创药业-U股市,海创药业-U股票价格,海创药业-U股票交易,海创药业-U股票购买,海创药业-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海创药业-U(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海创药业-U(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}